Prevention of chemotherapy-induced nausea and vomiting: Updated guidance from the BSMO supportive care task force
(2025) bjmo — Vol. 19, n° 1, p. 15-26 (2025)
Files
article1.pdf
Open Access - Adobe PDF
- 297.39 KB
Details
- Authors
- Abstract
- Nausea and vomiting continue to be some of the more dreaded side effects of anticancer therapy. While advances in the prophylaxis of chemotherapy induced nausea vomiting (CINV), and guidance from international cancer societies have yielded important benefits for cancer patients, there remains an important need to further improve patient care. To address the need for a better CINV prophylaxis, and to respond to the introduction of new potentially emetogenic anticancer agents and the publication of new clinical trial data with anti-emetic agents, several international oncological societies have recently updated their guidelines for the prevention of CINV. The objective of this paper was to translate these new international recommendations to a Belgian context.
- Affiliations
Citations
Fontaine, C., Collignon, J., Debruyne, P., Duck, L., Everaert, E., Feys, T., Langenaeken, C., LEBRUN, F., Mebis, J., Naert, E., Van Landuyt, P., Wuyts, S., van Marcke de Lummen, C. J., Vanryckeghem, F., Verschaeve, V., & Klastersky, J. (2025). Prevention of chemotherapy-induced nausea and vomiting: Updated guidance from the BSMO supportive care task force. bjmo, 19(1), 15-26. https://hdl.handle.net/2078.5/259460 (Original work published 2025)